Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 921-928

  Budman, Daniel R ^a   Soong, Richie ^c   Calabro, Anthony ^a   Tai, Julia ^a   Diasio, Robert ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Capecitabine; Dual tyrosine kinase inhibitor; Epidermal growth factor receptor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYTOTOXIC AGENT; DNA FRAGMENT; DOCETAXEL; DOXIFLURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GW 282974X; HISTONE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG SYNERGISM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 33748455687     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224457.36522.60     Document Type: Article

References (53)

1. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004; 9:58-67.
2. Asslan R, Pradines A, Pratx C, Allal C, Favre G, Le Gaillard F. Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells. Biochem Biophys Res Commun 1999; 260:699-706.
3. Budiyanto A, Bito T, Kunisada M, Ashida M, Ichihashi M, Ueda M. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol 2003; 121:1088-1094.
4. Gatzemeier U. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. Oncology (Huntington) 2003; 17:7-10.
5. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 2002; 86:1518-1523.
6. Pareja M, Sanchez O, Lorita J, Soley M, Ramirez I. Activated epidermal growth factor receptor (ErbB1) protects the heart against stress-induced injury in mice. Am J Physiol Regul Integr Comp Physiol 2003; 285:R455-R462.
7. 1 for cell cycle progression induced by bombesin and bradykinin. Am J Physiol Cell Physiol 2001; 281:C886-C898.
8. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565.
9. Gale DM. Molecular targets in cancer therapy. Semin Oncol Nurs 2003; 19:193-205.
10. Syed S, Rowinsky E. The new generation of targeted therapies for breast cancer. Oncology (Huntington) 2003; 17:1339-1351; discussion 1352, 1355-1356.
11. Santoro A, Cavina R, Latteri F, Zucali PA, Ginanni V, Campagnoli E, et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 2004; 15:33-37.
12. Vogel CL, Franco SX. Clinical experience with trastuzumab (herceptin). Breast J 2003; 9:452-462.
13. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
14. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006; 40:241-250.
15. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002; 21:5224-5232.
16. Schmidt M, Lichtner RB. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Update 2002; 5:11-18.
17. Hidalgo M. Erlotinib: preclinical investigations. Oncology (Huntington) 2003; 17:11-16.
18. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30:1-17.
19. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002; 38 (Suppl 5):S11-S18.
20. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86:819-827.
21. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-1639.
22. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
23. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61:7196-7203.
24. Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002; 13:1011-1016.
25. Budman DR, Calabro A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002; 74:41-46.
26. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000; 18:695-701.
27. Levitzski A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267:1782-1798.
28. Zhou H, Kim Y, Peletier A, McCall W, Earp H, Sartor C. Effects of the EGFR/ Her2 kinase inhibitor GW572016 on EGFR- and Her2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004; 58:344-352.
29. Xia W, Liu L, Ho P, Spector N. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive tot he dual EGFR/ErbB2 kinase inhibitor GW 572016. Oncogene 2004; 23:646-653.
30. Akiyama T, Kadooka T, Ogawara H. Purification of the epidermal growth factor receptor by tyrosine-Sepharose affinity chromatography. Biochem Biophys Res Commun 1985; 131:442-448.
31. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242:933-935.
32. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res 1994; 54:4703-4709.
33. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001; 44:338-348.
34. Davidson NE, Bronzert DA, Chambon P, Gelmann EP, Lippman ME. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Res 1986; 46:1904-1908.
35. Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1985; 1:216-223.
36. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3:2099-2106.
37. Egeblad M, Mortensen OH, van Kempen LC, Jaattela M. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells. Biochem Biophys Res Commun 2001; 281:25-31.
38. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-749.
39. Hiorns LR, Bradshaw TD, Skelton LA, Yu Q, Kelland LR, Leyland-Jones B. Variation in RNA expression and genomic DNA content acquired during cell culture. Br J Cancer 2004; 90:476-482.
40. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 2003; 63:2762-2770.
41. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
42. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79:196-202.
43. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994-8004.
44. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278:175-184.
45. Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res 2001; 7:3423-3429.
46. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83:249-289.
47. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27:21-25; discussion 92-100.
48. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluoridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
49. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntington) 1999; 13:17-21.
50. Budman DR. Capecitabine. Invest New Drugs 2000; 18:355-363.
51. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
52. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002; 49:211-216.
53. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, et al. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9:4735-4742.